Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of CSL689 in adults with congenital factor VII deficiency
NL-OMON43708Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Jul 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of CSL689 in congenital factor VII deficiency (3 arms), sponsored by CSL Limited. Primary endpoints: Elimination half-life of plasma factor VIIa activity, Maximum observed plasma factor VIIa activity and 1 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
CSL689
03
Conditions
congenital factor VII deficiency
Beyond the preview
Go deeper on NL-OMON43708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43708.